Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts

Ophthalmology

Volumn 105, Issue 7, 1998, Pages 1259-1264

  Vrabec, Tamara R ^a,d   Baldassano, Vincent F ^b   Whitcup, Scott M ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d WILLS EYE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; EYE PHOTOGRAPHY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; OPHTHALMOSCOPY; ORAL DRUG ADMINISTRATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RECURRENT DISEASE; RETINITIS; VIRUS LOAD;

EID: 0031686182     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)97031-2     Document Type: Article

References (24)

1. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:75-80.
2. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis 1993;168:557-63.
3. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73.
4. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997;126:264-74.
5. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
6. Pepose JS, Newman C, Bach MC, et al. Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir. Ophthalmology 1987;94:414-24.
7. Burd EM, Pulido JS, Puro DG, O'Brien WJ. Maintenance of replicative intermediates in ganciclovir-treated human cytomegalovirus-infected retinal glia. Arch Ophthalmol 1996;114:856-61.
8. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996;114:23-33.
9. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in Collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992;326:213-20.
10. Dunn JP, MacCumber MW, Forman MS, et al. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 1995;119:587-96.
11. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
12. Sullivan V, Biron KK, Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993;37:19-25.
13. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-53.
14. Miedema F, Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988;82:1908-14.
15. Gurley RJ, Ikeuchi K, Byrn RA, et al. CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A 1989;86:1993-7.
16. Chirmule N, Lesser M, Gupta A, et al. Immunological characteristics of HIV-infected children: relationship to age, CD4 counts, disease progression, and survival. AIDS Res Hum Retroviruses 1995;11:1209-19.
17. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA 1997;277:1519-20.
18. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997;124:199-205.
19. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
20. Baldassano V, Dunn JP, Feinberg J, Jabs DA. Cytomegalovirus retinitis and low CD 4+ T-lymphocyte counts [letter]. N Engl J Med 1995;333:670.
21. Egbert PR, Pollard RB, Gallagher JG, Merigan TC. Cytomegalovirus retinitis in immunosuppressed hosts. II: Ocular manifestations. Ann Intern Med 1980;93:664-70.
22. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ophthalmology 1994;101:1250-61.
23. Anand R, Nightingale SD, Fish RH, et al. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993;111:223-7.
24. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.